We, the undersigned shareholders, patients, and supporters of Northwest Biotherapeutics (NWBO), express our deep concern regarding the lack of transparency surrounding the company's Marketing Authorization Application (MAA) for DCVax-L. Nearly two years have passed since the initial submission on December 21, 2023, yet we have not received any substantive updates despite assurances of maintaining "continuous communication" with regulators.

DCVax-L represents a groundbreaking advancement in cancer treatment, promising to extend and improve quality of life for countless patients battling serious illness. As stakeholders invested in both the financial success of the company and the broader mission to combat cancer, we believe it is imperative for NWBO's leadership to uphold commitments of transparency and accountability.

Given the profound impact this treatment could have on public health and investor confidence, detailed communication regarding the progress, challenges, or any regulatory feedback pertaining to the MAA is crucial. Without such updates, shareholders are left in ambiguity, which not only fosters unnecessary anxiety but also undermines the trust between the company and its stakeholders.

We appreciate the complexity of the regulatory process. However, consistent and forthright communication from NWBO would reaffirm our collective commitment to advancing innovative healthcare. This petition is not only about safeguarding investments but also about ensuring that hope and advancements in cancer treatment are not stalled due to a lack of communication.

By signing this petition, we emphasize the importance of transparent dialogue and urge the NWBO management and Board of Directors to provide a comprehensive update on the DCVax-L MAA process. Let us come together to support this crucial step in revolutionizing cancer treatment while fostering an environment of trust and cooperation.